

file

SEP 17 1984

St. Luke's Methodist Hospital
ATTN: Samuel T. Wallace, President
1026 A. Avenue Northeast
Cedar Rapids, IA 52402

Re: Letter dated August 3, 1984 for amendment to NRC License No. 14-09883-01

Gentlemen:

In order to complete your amendment request please submit the following additional information:

1. Concerning your request for exemption from certain personnel monitoring requirements for nurses assigned to therapy patients, please submit the following:

- a. ALARA

Please submit a description of the steps you have taken to maintain exposure levels ALARA (e.g., the use of distance between patients, portable shields, barriers, etc).

- b. Documentation of Actual Exposures

Submit additional documentation concerning the maximum anticipated exposures nurses may receive when caring for therapy patients. Your documentation should include a description of the exposure levels expected in the therapy patients room where nurses are likely to be working and caring for the patients, the time the nurses spend in the patients' room, and an evaluation of the dose to nurses based on the criteria specified in 10 CFR Part 20, Section 20.202 and 20.101(a) (enclosed).

- c. Administrative Controls

Describe your procedures (e.g., rotating nurses assigned to therapy patients, time limits for nurses to remain in patients' room, surveys, surveillance, etc.) used to ensure that nurses will not receive doses in excess of the limits specified in 20.101(a).

2. Concerning your request to add Dr. R. Kundel to your license as an authorized user:

- a. Please submit documentation of Dr. Kundel's experience using phosphorous-32 soluble and/or colloidal for treating polycythemia vera, leukemia, bone metastases, and intracavitary treatment. This information is necessary in order to authorize Dr. Kundel for all of Group IV.

8507120203 841123
REG3 LIC30
14-09883-01 PDR

- b. Please specify the name of the physician, as well as the NRC license number on which he is listed, under whom Dr. Kundel received his training and experience using Groups IV and V materials.

We will continue our review of your application upon receipt of this information. Please reply in duplicate and refer to Control Number 77316.

To prevent an excessive delay in completing the processing of your licensing action, we request that you reply within thirty (30) days from the date of receipt of this letter.

If you have any questions or require clarification on any of the information stated above, you may contact us at (312) 932-2625.

Sincerely,

Original Signed
Patricia J. Whiston
Materials Licensing Section

Enclosure: As stated

R111

Whiston/as
09/07/84